Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 10, 2024

Survival After Sorafenib Plus TACE vs TACE Alone for Recurrent Intermediate-Stage Hepatocellular Carcinoma

JAMA Oncology

 

Additional Info

JAMA Oncology
Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial
JAMA Oncol 2024 Jun 20;[EPub Ahead of Print], W Fan, B Zhu, S Chen, Y Wu, X Zhao, L Qiao, Z Huang, R Tang, J Chen, WY Lau, M Chen, J Li, M Kuang, Z Peng

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading